06:44 AM EST, 11/10/2025 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) reported a Q3 net loss Monday of $0.52 per diluted share, widening from a loss of $0.20 a year earlier.

Three analysts polled by FactSet expected a loss of $0.45.

Revenue for the quarter ended Sept. 30 was $32.5 million, compared with $2.1 million a year earlier.

Analysts surveyed by FactSet expected $28.7 million.

As of Sept. 30, the company said it had $288.2 million in cash, cash equivalents, and short-term investments, and expected it could fund operations through cash-flow break-even.

Shares of the company were up 1.5% in recent Monday premarket activity.